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A B S T R A C T 
Oxidized form of avidin, named AvidinOX, provides stable fixation of biotinylated 
molecules in tissues, thus representing a breakthrough in topical treatments. AvidinOX 
proved to be a stable receptor for radiolabeled biotin, biotinylated antibodies and 
biotinylated cells. In order to expand applicability of the AvidinOX-based delivery platform, 
in the present study we investigated the possibility to hold biotinylated chemotherapeutics 
in AvidinOX-treated sites. A novel biotinylated Gimatecan-derived camptothecin coded 
ST8161, was injected at suboptimal doses into human tumors xenografted in mice, alone 
or pre-complexed to AvidinOX. Significantly higher tumor growth inhibition was observed 
when the drug was complexed to AvidinOX , suggesting the potential utility of this delivery 
modality for the local treatment of inoperable tumors. 
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The choice of anti-cancer therapy depends on the cancer’s type, location and stage of 
the disease. Methods of experimental cancer treatment are continuously under 
development. For localized inoperable cervical, prostate, breast, skin and many other 
cancers and, even for liver and pulmonary oligometastasis, brachytherapy has been 
recognized as an effective form of local irradiation1-5.  Brachytherapy can be performed by 
applying radiation sources within or close to the tumor by using devices charged with 
radioisotopes and the technology is meant to minimize the radioactive exposure of non-
target organs. Brachytherapy devices include balloons, catheters and permanent seeds 
requiring highly skilled medical personal and sophisticated after loading equipment to 
avoid radiation exposure of clinical staff6. Safety issues have been raised with 
brachytherapy procedures. Particularly, the injection of radioactive seeds has been 
reported to induce in some cases long-term complications due to seed migration to the 
brain7, heart8 or lung where they provoke embolization of pulmonary arteries9. 
We recently reported that the oxidized form of avidin named AvidinOX, exhibits the 
distinctive property to form Schiff’s bases with tissue proteins while maintaining the 
capacity of original avidin to bind biotin and biotin derivatives with high affinity10-13. 
AvidinOX provides stable fixation of radiolabeled biotin in tissues thus representing a new 
biological form of brachytherapy. This product is currently under investigation in phase I 
clinical trials for targeting 177Lutetium-biotinDOTA (177Lu-ST2210) to inoperable tumor 
lesions and liver metastases (ClinicalTrials.gov NCT02053324 and NCT03188328). Previous 
data from our group showed that AvidinOX can be employed for targeting diverse 
biotinylated therapeutics including cells14 and antibodies.15-17 Our studies indicated that 
AvidinOX-anchored antibodies including biotinylated Cetuximab (bCet) and Panitumumab 
(bPan) or Trastuzumab and Pertuzumab exhibit much higher inhibitory activity against 
tumor cells as compared to their original non-biotinylated versions. 
In order to expand applicability of the AvidinOX-based delivery platform, in the present 
paper we investigated the possibility to hold biotinylated chemotherapeutics in AvidinOX-
treated sites. Therefore, ST8161, a novel biotinylated camptothecin-derived agent, was 
complexed to AvidinOX and injected directly into the tumor in comparison with ST8161 
alone.  
Compound 1, named ST8161, was prepared according to the following procedure, also 
drawed in Figure 1. Compound 2 was activated as a chloroformate18 by treatment with 
triphosgene, then reacted with Gimatecan19 to afford carbonate 3.20 Removal of Boc 
protecting group by formic acid gave compound 4 in good yield.20 (+)-biotin N-succinimidyl 
ester was prepared according to procedure described earlier.21  Treatment of 4 with biotin 
N-succinimidyl ester and TEA in anhydrous DMF afforded compound 1 in 90% yield. 
Gimatecan was prepared as reported by Dallavalle and co-authors.22  
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Figure 1. a) triphosgene, Na2CO3, diethyl ether/toluene 1:1, 0 °C, 24 h, RT; b) 
Gimatecan, DIPEA, DMAP, CH2Cl2 (dry), 0 °C - RT, 24 h, 50%; c) HCOOH (98%), RT, 1.5 h, 
82%; d) biotin-NHS-ester, Et3N, DMF (dry), 2 h, RT, 90%. 
All experimental procedures and complete characterization of compounds are 
available in the Supporting Information. 
To investigate the inhibitory activity of biotinylated Gimatecan ST8161 on tumor cell 
proliferation, A431 squamous carcinoma cells were exposed to different concentrations of 
the drug (Fig. 2). The cells in logarithmic phase of growth were seeded in triplicate in 96-
well plate at concentration 3000 cells/well in DMEM 10% FBS with Gentamicin. Next day 
medium was aspirated and the cells were exposed to drug in fresh medium. Cells were 
incubated for 72 h. Calorimetric assay XTT was applied for analysis of cell proliferation. 
Plates were measured at 492nm-690nm with ELISA reader. IC50+SD was defined as the 
concentration required for 50% cell inhibition as compare to control cells. In two 
representative experiments IC50 value + SD of ST8161 was 9.25 + 0.778 nM.   
To verify accessibility and binding capacity of biotin in ST8161, competitive ELISA was 
performed. Multiwell plate (Immunoplate Maxisorb, Nunc, Roskilde, Denmark) was coated 
on at 4 °C with 100 µl of streptavidin solution at a concentration of 10 mg/mL in 50 mM 
NaHCO3, pH 9.6. After discarding coating solution, the plate was washed several times with 
washing buffer (0.05% Tween-20 in PBS) and blocked for one hour at 37 °C with blocking 
buffer (3% BSA fraction V, 0.05% Tween-20 in PBS). The plate was rinsed and incubated 
with biotinylated and non biotinylated drugs for one hour at 37 °C. The plate was washed 
and incubated with biotinylated AP (Sigma). Binding of AP-conjugated biotin was detected 
by incubation with 1 mg/mL solution of p-nitrophenyl phosphate in substrate buffer (10% 
diethanolamine buffer, 0.5 mM MgCl2, pH 9.8) for 15 min. The results were expressed as 
the difference between absorbances at 405 and 620 nm. Development of the plate in 
presence of non biotinylated Gimatecan and biotinylated ST8161 is shown on Fig. 3. 
Biotinylated ST8161 efficiently bound streptavidin and blocked development of reaction 
with biotinylated alkaline phosphatase.  
The efficacy of biotinylated toxin ST8161 to inhibit tumor growth in vivo in the 
presence or without AvidinOX was investigated in a mouse tumor xenograft model by using 
SKOV-3 ovarian carcinoma cell line.  
All the procedures adopted for housing and handling animals were in strict compliance 
with directive 2010/63/UE on the protection of animals used for scientific purposes, made 
effective in Italy by the Legislative degree 4 March 2014, n. 26, and ARRIVE guidelines.23 
SKOV-3 human ovarian adenocarcinoma cell exponentially growing cells were injected 
subcutaneously into nude Nu/Nu mice (day zero) (5x106/mouse in 100 µL) followed by 
caliper measurements.  
AvidinOX was prepared by Areta International in lyophilized form, as previously 
described (Verdoliva et al, 2010). After reconstitution with sterile water, the protein was 
10.0 mg/mL in acetate buffer pH 5.2 with mannitol and NaCl. Small aliquots of AvidinOX 
solution were stored at -80 °C. For preparation of a single mouse dose of conjugate 10 uL 
of AvidinOX were mixed with 0.67 µL of 10 mM ST8161 and incubated for 30 min at RT.  
On day 18 after tumor cell injection, when tumors were about 100 mm3, mice were 
randomized in groups of 8 mice in each and injected with a single intratumor injection of 
vehicle control (PBS,  10 µL), or ST8161 (6.7 nmol of a 10 mM solution, that is 5.7 µg/mouse 
or 0.26 mg/kg), or AvidinOX (10 µL of 10 mg/mL solution) or the combination AvidinOX 
+ST8161 (preincubated for 30 min before the administration). Tumor growth was 
controlled by a digital Vernier caliper twice a week until sacrifice.  
Upon 32 days after the single administration, mice treated with ST8161 showed a 
significant antitumor activity (TVI=48%, P<0.05 vs vehicle treated group), whereas the 
combination AvOX + ST8161 increased the antitumor effect (TVI= 68%, P<0.05 vs vehicle 
and vs ST8161 alone, Mann-Whitney’s test), Fig. 4a. The compounds revealed a good 
tolerability as shown for body weight (Fig. 4b).  
Gimatecan is a synthetic analog of camptothecin, a cytotoxic quinoline alkaloid which 
inhibits the DNA enzyme topoisomerase I. In our study the ST8161, a biotinylated 
derivative of Gimatecan, was delivered locally into the site of the human xenograft in 
murine tumor model in combination with AvidinOX or alone. Our results demonstrated 
that the best antitumor efficacy was achieved by administration of 
AvidininOX/biotinylated drug complex. ST8161 bound to four binding sites on AvidinOX 
and probably resided inside the tumor for a longer time and was released by degradation 
of linker.  The linker selected for Gimatecan-biotin conjugation was designed to guarantee 
releasing of cytotoxic drug under acidic (carbonate bond to 20-OH position of CPT) and 
reducing conditions (disulfide moiety) by GSH, typical of the tumor microenvironment.24 
The half-life of AvidinOX injected into normal tissue and solid tumors was previously shown 
to be about 14 and 7 days, respectively.13,25 We assumed that the AvidinOX was continuing 
anchorage the ST8161 in tumor until the linker between Gimatecan and biotin degraded, 
thus providing efficient therapy by a single injection. We observed no variation of the 
weight in ST8161-treated mice as compared to vehicle controls. This observation indicated 
that general toxicity of ST8161 anchored into the tumor was low, thus making this 
therapeutic approach very promising for further investigation.  
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 Figure 2.  Effect of ST8161 on the growth of A431 cells. 
 
 
 
Fig. 3. Competition of biotinylated ST8161 for streptavidin binding. Gimatecan was used 
as a negative non-biotinylated control.  
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Fig. 4. a) Tumors were allowed to develop in Nu/Nu mice for 18 
days after s.c. injection of 5x106 SKOV-3 ovarian tumor cells. 
Lesion development and response to the biotinylated toxin 
alone and in combination with AvOX was monitored using a 
Vernier calyper.  
 
Fig. 4. b) Body weight of SKOV-3 tumor bearing mice, 
throughout the experiment in a). 
 
 
